share_log

DEFA14A: Others

DEFA14A: Others

DEFA14A:其他
美股sec公告 ·  04/22 08:20
Moomoo AI 已提取核心訊息
Bristol-Myers Squibb, a leading pharmaceutical company, has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement. This filing, made under Schedule 14A of the Securities Exchange Act of 1934, indicates that the materials are intended to provide further information to shareholders in connection with the company's upcoming decisions. The filing confirms that no additional filing fee is required for these materials. The proxy statement and additional materials are a standard part of the shareholder voting process, allowing Bristol-Myers Squibb's shareholders to be fully informed before casting their votes on corporate matters.
Bristol-Myers Squibb, a leading pharmaceutical company, has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement. This filing, made under Schedule 14A of the Securities Exchange Act of 1934, indicates that the materials are intended to provide further information to shareholders in connection with the company's upcoming decisions. The filing confirms that no additional filing fee is required for these materials. The proxy statement and additional materials are a standard part of the shareholder voting process, allowing Bristol-Myers Squibb's shareholders to be fully informed before casting their votes on corporate matters.
領先的製藥公司百時美施貴寶已向美國證券交易委員會(SEC)提交了明確的補充材料,作爲其委託書的一部分。該文件是根據1934年《證券交易法》附表14A提交的,表明這些材料旨在向股東提供與公司即將作出的決定有關的更多信息。該文件證實,這些材料不需要額外的申請費。委託書和其他材料是股東投票過程的標準部分,使百時美施貴寶的股東能夠在就公司事務進行表決之前充分了解情況。
領先的製藥公司百時美施貴寶已向美國證券交易委員會(SEC)提交了明確的補充材料,作爲其委託書的一部分。該文件是根據1934年《證券交易法》附表14A提交的,表明這些材料旨在向股東提供與公司即將作出的決定有關的更多信息。該文件證實,這些材料不需要額外的申請費。委託書和其他材料是股東投票過程的標準部分,使百時美施貴寶的股東能夠在就公司事務進行表決之前充分了解情況。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息